×
S&P 500   3,980.58 (+0.99%)
DOW   32,110.03 (+0.57%)
QQQ   291.22 (+1.39%)
AAPL   140.62 (+0.19%)
MSFT   262.98 (+1.29%)
FB   183.32 (+1.13%)
GOOGL   2,116.81 (-0.12%)
AMZN   2,146.06 (+3.08%)
TSLA   663.82 (+5.68%)
NVDA   169.07 (+4.66%)
BABA   82.65 (+0.22%)
NIO   14.45 (-1.23%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.21 (+2.39%)
T   21.25 (+0.43%)
GE   73.63 (-1.19%)
F   12.69 (+2.17%)
DIS   102.99 (+1.38%)
AMC   11.52 (+10.88%)
PFE   53.70 (+0.54%)
PYPL   79.81 (+1.47%)
NFLX   186.64 (+3.49%)
S&P 500   3,980.58 (+0.99%)
DOW   32,110.03 (+0.57%)
QQQ   291.22 (+1.39%)
AAPL   140.62 (+0.19%)
MSFT   262.98 (+1.29%)
FB   183.32 (+1.13%)
GOOGL   2,116.81 (-0.12%)
AMZN   2,146.06 (+3.08%)
TSLA   663.82 (+5.68%)
NVDA   169.07 (+4.66%)
BABA   82.65 (+0.22%)
NIO   14.45 (-1.23%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.21 (+2.39%)
T   21.25 (+0.43%)
GE   73.63 (-1.19%)
F   12.69 (+2.17%)
DIS   102.99 (+1.38%)
AMC   11.52 (+10.88%)
PFE   53.70 (+0.54%)
PYPL   79.81 (+1.47%)
NFLX   186.64 (+3.49%)
S&P 500   3,980.58 (+0.99%)
DOW   32,110.03 (+0.57%)
QQQ   291.22 (+1.39%)
AAPL   140.62 (+0.19%)
MSFT   262.98 (+1.29%)
FB   183.32 (+1.13%)
GOOGL   2,116.81 (-0.12%)
AMZN   2,146.06 (+3.08%)
TSLA   663.82 (+5.68%)
NVDA   169.07 (+4.66%)
BABA   82.65 (+0.22%)
NIO   14.45 (-1.23%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.21 (+2.39%)
T   21.25 (+0.43%)
GE   73.63 (-1.19%)
F   12.69 (+2.17%)
DIS   102.99 (+1.38%)
AMC   11.52 (+10.88%)
PFE   53.70 (+0.54%)
PYPL   79.81 (+1.47%)
NFLX   186.64 (+3.49%)
S&P 500   3,980.58 (+0.99%)
DOW   32,110.03 (+0.57%)
QQQ   291.22 (+1.39%)
AAPL   140.62 (+0.19%)
MSFT   262.98 (+1.29%)
FB   183.32 (+1.13%)
GOOGL   2,116.81 (-0.12%)
AMZN   2,146.06 (+3.08%)
TSLA   663.82 (+5.68%)
NVDA   169.07 (+4.66%)
BABA   82.65 (+0.22%)
NIO   14.45 (-1.23%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.21 (+2.39%)
T   21.25 (+0.43%)
GE   73.63 (-1.19%)
F   12.69 (+2.17%)
DIS   102.99 (+1.38%)
AMC   11.52 (+10.88%)
PFE   53.70 (+0.54%)
PYPL   79.81 (+1.47%)
NFLX   186.64 (+3.49%)
NASDAQ:GWPH

GW Pharmaceuticals (GWPH) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$218.96
$218.96
50-Day Range
$216.90
$219.28
52-Week Range
$87.07
$219.57
Volume
N/A
Average Volume
899,771 shs
Market Capitalization
$6.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.15

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GW Pharmaceuticals logo

About GW Pharmaceuticals

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GWPH
Fax
N/A
Employees
1,161
Year Founded
N/A

Sales & Book Value

Annual Sales
$311.33 million
Cash Flow
$0.01 per share
Book Value
$23.48 per share

Profitability

Net Income
$-9.02 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$6.86 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2020
Today
5/25/2022

MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

1072nd out of 1,420 stocks

Pharmaceutical Preparations Industry

528th out of 678 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) posted its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.27. The biopharmaceutical company had revenue of $137.10 million for the quarter, compared to analyst estimates of $97.66 million. GW Pharmaceuticals had a negative trailing twelve-month return on equity of 7.46% and a negative net margin of 11.05%. GW Pharmaceuticals's quarterly revenue was up 50.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) earnings per share.
View GW Pharmaceuticals' earnings history
.

Who are GW Pharmaceuticals' key executives?
GW Pharmaceuticals' management team includes the following people:
What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among GW Pharmaceuticals' employees.

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $218.96.

How much money does GW Pharmaceuticals make?

GW Pharmaceuticals has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9.02 million in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does GW Pharmaceuticals have?

GW Pharmaceuticals employs 1,161 workers across the globe.

What is GW Pharmaceuticals' official website?

The official website for GW Pharmaceuticals is www.gwpharm.com.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected].

This page was last updated on 5/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.